stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Revenue growth
argenex SE's revenue growth over the twelve months to 30 September 2026 was 60.8%, down 27.8 percentage points from fiscal 2025 (88.6%). Over the past ten years it has ranged from −56.7% (fiscal 2016) to 731.0% (fiscal 2021); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 88.6% | 11.11 |
| FY2024 | 77.5% | (107.39) |
| FY2023 | 184.9% | 202.36 |
| FY2022 | −17.5% | (748.46) |
| FY2021 | 731.0% | 760.83 |
| FY2020 | −29.8% | (197.75) |
| FY2019 | 167.9% | 193.90 |
| FY2018 | −26.0% | (171.65) |
| FY2017 | 145.7% | 202.42 |
| FY2016 | −56.7% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 52.1% | (7.33) |
| Jun 2026 | 59.5% | (3.24) |
| Mar 2026 | 62.7% | (11.11) |
| Dec 2025 | 73.8% | (21.65) |
| 25 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| RVMD Revolution Medicines, Inc. compare | 491.1% |
| ARGX argenex SE | 60.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 32.9% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 18.6% |
| RPRX Royalty Pharma PLC compare | 11.4% |
| MRNA Moderna, Inc. compare | −27.6% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement